Exchange: NASDAQ·Updated 03:39 PM EDT
OTLK logo

OTLK Outlook Therapeutics Inc

$0.6667
$0.0063
(0.94%)
Today
EarningsDec 18
Mkt Cap$163.84M
Vol6.72M

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
44

Bearish Sentiment

How do you feel about OTLK?

Advertisement|Remove ads.